HOME >> BIOLOGY >> NEWS
Study shows drug blocks breast cancer migration to bone

An international research team has identified what may be a critical molecule in the ability of tumours to metastasize -- or spread -- into bone. The research, initiated at the University of Toronto and continued at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, found that a protein in bone called RANKL appears to communicate with a receptor in breast, prostate and skin cancer cells -- telling them to migrate. Moreover, a drug already known to block RANKL's activity may prevent cancers from spreading into the bone.

Roughly 120 years ago, scientists predicted that bone tissue might manufacture certain molecules that entice cancer cells to lodge there. More people die of metastases -- secondary tumours that develop elsewhere in the body -- than from their initial tumours and bone is particularly fertile "soil" for travelling cancer "seed" cells. It has been estimated that 70 per cent of patients with progressive breast cancer and 84 per cent of prostate cancer patients develop bone metastases.

D. Holstead Jones, a former post-doctoral fellow in Professor Josef Penninger's laboratory of medical biophysics and immunology at U of T, is the lead author of the paper, which appears in the March 30 issue of the journal Nature. The team also included researchers from the University of Western Ontario's Department of Physiology and Pharmacology. Josef Penninger is currently the director of the IMBA in Vienna, where the project is being continued.

Jones and her colleagues show that RANKL, a cytokine protein which is produced at high levels in bone marrow, acts on breast, prostate and skin cancer cells through the RANK receptor. Over the past few years, Penninger's lab had determined that RANKL is essential in both bone breakdown and in controlling the growth of cells that form a lactating mammary gland. Putting these two discoveries together, the team decided to study the link between breast cancer and bon
'"/>

Contact: Nicolle Wahl
nicolle.wahl@utoronto.ca
416-978-6974
University of Toronto
29-Mar-2006


Page: 1 2 3

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study shows drug blocks breast cancer migration bone

(Date:5/23/2013)... Science , Automated conserved noncoding ... promoter evolution among grasses , Within the genome ... DNA that undergo little change in position and sequence ... any proteins. Some of these evolutionarily stable sequences, so-called ... expression of other genes or the condensation of chromosomes, ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Wash. Pacific Northwest National Laboratory honored more ... commercialization of intellectual property at PNNL,s annual Intellectual ... , The Department of Energy national laboratory named ... for his work developing battery materials that can ... the electrical grid, and reduce the time it ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)...  Saddleback Memorial Medical Center in Laguna ... on the West Coast to perform a hysterectomy using ... women with a state-of-the-art, minimally invasive approach to gynecological ... , M.D., a highly regarded Orange County ... minimally invasive surgery at Saddleback Memorial, led the surgical ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy.  ... ASCO annual meeting is the pre-eminent conference focused on ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
Cached News: